Iconovo
  • Home
  • About us
    • About us
    • Board of Directors
    • Management
    • Our Team
    • Career
  • Products
    • Products
    • ICOres
    • ICOcap
    • ICOpre
    • ICOone
    • Patents
  • Capabilities
    • Capabilities
    • Devices
    • Formulation
    • Characterization
    • General Support
  • Collaborations
  • Investors
    • Investors
    • Aktien
    • Pressmeddelanden
    • Finansiella rapporter
    • Kalender och event
    • Bolagsstyrning
  • News
  • Contact
  • Search
  • Menu
  • LinkedIn

Initial Public Offering (IPO) 2018 (Only in Swedish)

News

Läs om Iconovos teckningserbjudande här.

March 2, 2018/by Mea Lindsjö
Share this entry
  • Share on Twitter
  • Share on LinkedIn
  • Share by Mail
https://iconovo.se/wp-content/uploads/2021/03/Breathtaking-innovation_Iconovo.png 0 0 Mea Lindsjö https://iconovo.se/wp-content/uploads/2021/03/Breathtaking-innovation_Iconovo.png Mea Lindsjö2018-03-02 14:49:422018-03-02 14:49:42Initial Public Offering (IPO) 2018 (Only in Swedish)

Possessing a unique combination

of engineering and pharmaceutical expertise, Iconovo can provide the optimal combination of uniquely designed inhalers and tailored formulations

ICONOVO AB

VISITING ADDRESS
Medicon Village, Lund
Scheeletorget 1, Bld 406

POSTAL ADDRESS
Iconovo AB
Medicon Village
SE-223 81 LUND
Sweden

CONTACT

Phone: +46 46 275 67 77

VP Business Development
Roger Lassing
Mail: roger.lassing@iconovo.se

CEO
Johan Wäborg
Mail: johan.waborg@iconovo.se

SITEMAP

  • Home
  • Capabilities
  • Investors

Press releases

Subscribe

Follow us on Linkedin

Annual Report 2017 (Only in Swedish) Iconovo are mentioned in Swedish business media (Only in Swedish)
Scroll to top